Decline in Core Pharmaceutical Sales Due to Generic Drugs
First written in FY2016-Q2. 22 of 29 entries say "Restated". Latest entry: 2026-07-31.
The whole theme swung hardest in 2017: 4 of 7 companies on the "Worse" side.
0 other companies' latest entry also says "Mitigated".
- FY2025RestatedAnnual report
「In the United States, the exclusive marketing period for the product as a treatment for autosomal dominant polycystic kidney disease (ADPKD) ended in April 2025, and generic drugs were launched, resulting in lower sales revenue. Sales revenue also declined in Europe and Japan due to the impact of generic drugs. As a result, sales revenue was ¥221,910 million, down 21.1% from the previous fiscal year.」
For Samsca/Jynarque, the launch of generic drugs following the end of the exclusive marketing period for the ADPKD indication in the United States, and the decline in sales revenue including Japan and Europe, have been documented. - FY2025-H1WorsenedAnnual report
「In the United States, the exclusive marketing period for the product as a treatment for autosomal dominant polycystic kidney disease (ADPKD) ended in April 2025, and generic drugs have been launched. However, sales revenue increased due to ongoing information-provision activities and other factors. In Europe and Japan, sales revenue declined due to the impact of generic drugs.」
For Samsca/Jynarque, the end of the exclusive marketing period and the launch of generic drugs for the ADPKD indication in the United States have newly occurred, while sales revenue in Japan and Europe continues to decline due to generic drugs. - FY2024RestatedAnnual report
「Sales revenue declined in Europe and Japan due to the impact of generic drugs.」
For Samsca/Jynarque, sales revenue increased in the United States, while the decline in sales revenue due to generic drugs continued in Japan and Europe. - FY2024-H1WorsenedAnnual report
「In Japan, the exclusive marketing period for the ADPKD indication ended in March 2024. Sales revenue also declined due to the impact of generic drugs for the indication of fluid retention associated with heart failure and cirrhosis. In Europe, sales revenue declined due to the impact of generic drugs.」
For Samsca/Jynarque, the exclusive marketing period for the ADPKD indication in Japan has ended, and sales revenue has declined due to the impact of generic drugs for certain indications in Japan and in Europe. - FY2024-Q1RestatedAnnual report
「In Japan, the number of prescriptions for autosomal dominant polycystic kidney disease (ADPKD) is increasing, and the number of patients with treatment experience has exceeded 10,000. Meanwhile, sales revenue declined due to the impact of the launch of generic drugs for the indication of fluid retention associated with heart failure and cirrhosis. In the United States, where the product is sold as a treatment for hyponatremia, sales revenue also declined sharply due to the impact of the launch of generic drugs.」
For Samsca, prescriptions in the ADPKD field are expanding, while sales revenue in Japan and the United States continues to decline following the launch of generic drugs. - FY2023RestatedAnnual report
「In Japan, the number of prescriptions for autosomal dominant polycystic kidney disease (ADPKD) is increasing, and the number of patients with treatment experience has exceeded 10,000. Meanwhile, sales revenue declined sharply due to the impact of the launch of generic drugs for the indication of fluid retention associated with heart failure and cirrhosis. In the United States, where the product is sold as a treatment for hyponatremia, sales revenue also declined sharply due to the impact of the launch of generic drugs.」
For Samsca, the expansion of prescriptions in the ADPKD field has continued, while sales revenue in Japan and the United States continues to decline sharply following the launch of generic drugs. - FY2023-Q3RestatedAnnual report
「Meanwhile, sales revenue declined sharply due to the impact of the launch of generic drugs for the indication of fluid retention associated with heart failure and cirrhosis. In the United States, where the product is sold as a treatment for hyponatremia, sales revenue also declined sharply due to the impact of the launch of generic drugs. As a result, sales revenue was ¥36,928 million, down 47.8% year on year.」
For Samsca, a continued sharp decline in sales revenue due to the launch of generic drugs in Japan and the United States has resulted in sales revenue declining 47.8% year on year. - FY2023-Q2RestatedAnnual report
「In Japan, the number of prescriptions for autosomal dominant polycystic kidney disease (ADPKD) is steadily increasing, but sales revenue declined sharply due to the impact of switching to generic drugs for the indication of fluid retention associated with heart failure and cirrhosis. In the United States, where the product is sold as a treatment for hyponatremia, sales revenue also declined sharply due to the impact of switching to generic drugs.」
For Samsca, a continued sharp decline in sales revenue due to switching to generic drugs in Japan and the United States has been documented. - FY2023-Q1RestatedAnnual report
「In Japan, where the product is sold as a treatment for fluid retention associated with heart failure and cirrhosis and for autosomal dominant polycystic kidney disease (ADPKD), sales revenue declined sharply due to the impact of switching to generic drugs for the indication of fluid retention associated with heart failure and cirrhosis. In the United States, where it is sold as a treatment for hyponatremia, sales revenue also declined sharply due to the impact of switching to generic drugs. As a result, sales revenue was ¥12,278 million, down 46.8% year on year.」
For Samsca, a continued sharp decline in sales revenue due to switching to generic drugs in Japan and the United States has been documented. - FY2022RestatedAnnual report
「In the United States, where the product is sold as a treatment for hyponatremia, and in Europe, where it is sold as a treatment for hyponatremia caused by the syndrome of inappropriate antidiuretic hormone secretion (SIADH), generic drugs have been launched following the expiration of the exclusive marketing period.」
For Samsca, the launch of generic drugs following the expiration of the exclusive marketing period in the United States and Europe continues. - FY2022-Q3RestatedAnnual report
「In Japan, where the product is indicated for fluid retention associated with heart failure and cirrhosis, in the United States, where it is sold as a treatment for hyponatremia, and in Europe, where it is sold as a treatment for hyponatremia caused by the syndrome of inappropriate antidiuretic hormone secretion (SIADH), generic drugs have been launched following the expiration of the exclusive marketing period.」
The situation in which generic drugs have been launched for Samsca following the expiration of exclusive marketing periods in Japan, the United States and Europe continues to be documented. - FY2022-Q1RestatedAnnual report
「In the United States, where the product is sold as a treatment for hyponatremia, and in Europe, where it is sold as a treatment for hyponatremia caused by the syndrome of inappropriate antidiuretic hormone secretion (SIADH), generic drugs have been launched following the expiration of the exclusive marketing period.」
The situation in which generic drugs have been launched for Samsca following the expiration of the exclusive marketing period in the United States and Europe continues to be documented. - FY2021RestatedAnnual report
「In the United States, where the product is sold as a treatment for hyponatremia, and in Europe, where it is sold as a treatment for hyponatremia caused by the syndrome of inappropriate antidiuretic hormone secretion (SIADH), generic drugs have been launched following the expiration of the exclusive marketing period.」
For Samsca, the launch of generic drugs following the expiration of exclusive marketing periods in the United States and Europe, and the impact on sales of core pharmaceuticals, continue to be explained. - FY2021-Q1RestatedAnnual report
「In the United States, where the product is sold as a treatment for hyponatremia, generic drugs have been launched following the expiration of the exclusive marketing period. As a result, sales revenue was ¥20,787 million, down 6.7% year on year.」
The launch of generic drugs in the United States following the expiration of Samsca’s exclusive marketing period and the resulting decline in sales revenue continue to be documented. - FY2020RestatedAnnual report
「In the United States, where the product is sold as a treatment for hyponatremia, generic drugs have been launched following the expiration of the exclusive marketing period.」
For Samsca, the launch of generic drugs in the United States following the expiration of the exclusive marketing period has also occurred, and the impact of the end of exclusive marketing periods and generic drugs on sales of core pharmaceuticals continues to be documented. - FY2019RestatedAnnual report
「In the healthcare-related business, we are working to extend product life cycles through additional indications and dosage-form changes. However, after the protection period for patents that the Group is entitled to use exclusively expires, competition is expected to intensify as generic drugs competing with pharmaceuticals manufactured or sold by the Group emerge, which may have a material impact on the Group’s operating results and financial position.」
The risk of intensified competition from generic drugs after patent protection expires, and measures to extend product life cycles through additional indications and dosage-form changes, continue to be documented. - FY2018-Q3RestatedAnnual report
「In the central nervous system field, sales revenue from the antipsychotic Abilify declined year on year due to the impact of generic drugs and the April 2018 drug price revision. Meanwhile, sales revenue from Abilify Maintena, a long-acting injectable administered once monthly, has steadily increased as the number of prescriptions has grown.」
While sales revenue from Abilify itself continues to decline due to generic drugs and the drug price revision, an increase in prescriptions and sales revenue for the long-acting injectable has been documented. - FY2018-Q2RestatedAnnual report
「In the central nervous system field, sales revenue from the antipsychotic Abilify declined year on year due to the impact of generic drugs and the April 2018 drug price revision. Meanwhile, prescriptions for Abilify Maintena, a long-acting injectable administered once monthly, have steadily increased, resulting in a substantial rise in sales revenue.」
While sales revenue from Abilify itself continues to decline due to generic drugs and the drug price revision, increased prescriptions and higher sales revenue for the long-acting injectable have been documented. - FY2018-Q1RestatedAnnual report
「In the central nervous system field, sales revenue from the antipsychotic Abilify declined year on year due to the impact of generic drugs from June 2017 onward. Meanwhile, sales revenue from Abilify Maintena, a long-acting injectable administered once monthly, has increased as the number of cases has steadily grown in its third year on the market.」
While sales revenue from Abilify itself continues to decline following the launch of generic drugs, an increase in cases and higher sales revenue for Abilify Maintena has been documented. - FY2017RestatedAnnual report
「In the central nervous system field, sales of the antipsychotic Abilify declined from the previous fiscal year, reflecting the market expansion re-pricing applied in the April 2016 drug price revision and the launch of generic drugs from June 2017 onward.」
The continued decline in Abilify sales due to the drug price revision, market expansion re-pricing and the launch of generic drugs is being explained. - FY2017-Q3RestatedAnnual report
「In the central nervous system field, sales of the antipsychotic Abilify declined year on year, reflecting the market expansion re-pricing applied in the April 2016 drug price revision and the impact of generic drugs from June 2017.」
The continued decline in Abilify sales due to the launch of generic drugs and the impact of the drug price revision is being explained. - FY2017-Q2RestatedAnnual report
「In the central nervous system field, the number of prescriptions for the antipsychotic Abilify is increasing, but sales of the drug declined year on year, reflecting the application of a market expansion re-pricing rule in the April 2016 drug price revision.」
The continued increase in the number of Abilify prescriptions, alongside a decline in sales due to the drug price revision and market expansion re-pricing, is being explained. - FY2016RestatedAnnual report
「Sales of the antiplatelet agent Pletaal declined from the previous fiscal year, reflecting the promotion of generic drug use and a drug price revision in Japan.」
The continued decline in sales of Abilify, Pletaal and other products due to the end of exclusive marketing periods, generic drugs and drug price revisions is being explained. - FY2016-Q3RestatedAnnual report
「Global sales of Abilify declined year on year, reflecting the end of the exclusive marketing period in Europe and the United States and a drug price revision in Japan.」
The decline in Abilify sales due to the end of the exclusive marketing period, among other factors, continues to be documented, while a decline in sales of Busulfex due to the launch of generic drugs in the United States has also been documented. - FY2016-Q2First statedAnnual report
「Global sales of the antipsychotic Abilify declined by more than 70% year on year, reflecting the end of the exclusive marketing period in Europe and the United States. In the United States, generic drugs were approved in April 2015, resulting in a sharp decline of approximately 90% in sales year on year.」
The decline in sales of core products following the end of the exclusive marketing period and the approval and launch of generic drugs has actually occurred.